Share page on Facebook Share page on Twitter Share page on LinkedIn Home Insights Blog Blog 10 November 2021 EC proposes extended transition period for IVDR compliance The European Commission has issued a proposal for a modified rollout of the new In Vitro Diagnostic Regulation (IVDR). 01 November 2021 Diverse clinical research starts with the healthcare workforce Diversity initiatives are a hallmark of clinical research. From US Food and Drug Administration (FDA)-penned guidance and pharma initiatives. 31 October 2021 How we can continue building a diverse, equal, and inclusive industry Workplace diversity encourages collaboration and innovation – every team member brings their own unique backgrounds, experiences, and perspectives at ICON. 26 October 2021 Navigating cardiovascular clinical trial adjudication during a respiratory pandemic COVID-19 disrupted clinical trials across all indications. Patient enrolment, participation, data collection, and more was forced to adapt to the challenges of this virus. 19 October 2021 The impact of the COVID-19 pandemic on mental health Learn how the ongoing state of the COVID-19 pandemic has affected the global mental health crisis. 01 October 2021 ICON Joins UNICEF Corporate Vaccine Alliance ICON is one of seven leading Irish companies that just endorsed an open letter urging fellow corporate leaders to join the UNICEF Corporate Vaccine Alliance. 20 September 2021 Rare disease patients and advocates drive change in public policy Learn how patient advocacy organisations and rare disease communities are driving change in US public policy to make safe and effective treatment options available to all patients. 19 August 2021 The promise of glycomics in medicine Glycomics has been a largely overlooked area of study. Nevertheless, it has the potential to have a significant impact on precision medicine and healthcare as a whole. 18 August 2021 Battling HIV on many fronts Discover how in-home services and a global development strategy can help us get closer to more effective treatments. 17 August 2021 Anatomic pathology in the digital age The development of new, innovative digital technologies has provided the tools to rethink the way we design and conduct clinical trials. One area that has been particularly impacted by this digital age is anatomical pathology. 06 August 2021 Assessing the need for primary supporting clinical evidence or post-market clinical follow-up under MDR Discover why identifying the study objective during the planning process for PMCF studies is a critical step in the transition to MDR. 28 June 2021 Legacy devices under MDR/IVDR: a path forward Regulations from 2017 set stricter requirements on manufacturers product development, data reporting, and quality assurance in place. 23 June 2021 Health Technology Assessment: informal deal between council and European Parliament In June 2021, representatives of the European Parliament and the Council of European Union reached an agreement to boost cooperation amongst EU member States on HTA. 22 June 2021 Leveraging in-home services for Parkinson’s Disease New technologies like wearables and mobile devices, in-home services, and increased patient engagement can change the way we treat Parkinson's disease. 21 June 2021 MDR & IVDR bottlenecks: Challenges persist despite deadlines The new In Vitro Diagnostics Regulation (IVDR) and Medical Device Regulation (MDR) provide regulatory frameworks and conformity assessments that promote medical device safety and efficacy. 11 June 2021 How to improve participation of asymptomatic patients in neurodegenerative disease registries Insight into the power of patient-registries and how they can be used to increase participation of neurodegenerative patients. 18 May 2021 New procedures for drug prices negotiations and reimbursement in Italy In March 2021 the Italian Medicines Agency adopted new guidelines for drug pricing and reimbursement decisions. 14 May 2021 10 lessons learned about secondary “real world” data strategy Insights and lessons learned about operationalizing the use of real world data. 10 May 2021 Managed access programs as an alternative to long-term follow up studies Managed Access Programs (MAPs), are one solution for early access to investigational products that are gaining traction. 26 April 2021 The data revolution: Big data’s role in clinical trial patient recruitment, retention and engagement How big data can be leveraged by pharma to solve key challenges in patient recruitment and drug development. Load More IN THIS SECTION Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel Early engagement and regulatory considerations for biotech Decentralised & hybrid clinical trials Connect with us Contact us Submit proposal request Update Email Preferences Global office locator ICON on social media What's happening in ICON Contact About ICON Results & Reports For Clients Therapeutics Services Insights Innovation Content Preferences Office locations ICON For Patients Volunteers Investigators Jobs & Careers Investors Suppliers News & Events Press Releases Mediakit Events Social Media Dashboard LinkedIn Twitter Facebook Youtube © 2021 ICON plc Disclaimer Privacy Site Cookies